A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the long-term, drug-free ...
The following is a summary of “Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With ...
A study on the long-term safety of CAR T-cell therapy for B-cell lymphoma patients reveals a favourable safety profile with ...
The Brighterside of News on MSN3d
New CAR-T therapy achieved complete remission in 70% of aggressive cancer patientsCAR-T cell therapy has revolutionized the treatment of relapsed and refractory B-acute lymphoblastic leukemia (B-ALL), with ...
Autolus Therapeutics' main focus is on obe-cel, a CAR T-cell therapy for B-cell ALL, with a strong likelihood of approval.
IN8bio (INAB) unveiled INB-600, its next generation gammadelta T cell-based TCE platform. It is designed to address one of the biggest ...
Ongoing Phase 1 and Phase 2 clinical programs continue to exhibit long-term durable remissions in hard-to-treat cancers, ...
Proprietary platform represents the first known approach capable of sustained γδ T cell expansion, eliminating target cells with robust potency; INB-619, a next generation γδ ...
Matthew Matasar, MD, discusses odronextamab and the ongoing phase 1 ELM-1 trial in patients with CD20-positive B-cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback